Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals (TERN) Stock Price & Analysis


TERN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.26 - $14.04
Previous Close$6.81
Average Volume (3M)528.95K
Market Cap
Enterprise Value$151.90M
Total Cash (Recent Filing)$266.60M
Total Debt (Recent Filing)$770.00K
Price to Earnings (P/E)-5.4
Mar 26, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding61,794,522
10 Day Avg. Volume780,753
30 Day Avg. Volume528,946
Standard Deviation0.31
Financial Highlights & Ratios
Price to Book (P/B)1.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.73
Price Target Upside89.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6



Ownership Overview

17.81% Mutual Funds
73.13% Other Institutional Investors
9.06% Public Companies and
Individual Investors


What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $3.26 and its highest was $14.04 in the past 12 months.
    What is Terns Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Terns Pharmaceuticals’s upcoming earnings report date?
    Terns Pharmaceuticals’s upcoming earnings report date is Mar 26, 2024 which is in 107 days.
      How were Terns Pharmaceuticals’s earnings last quarter?
      Terns Pharmaceuticals released its earnings results on Nov 14, 2023. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.306 by -$0.114.
        Is Terns Pharmaceuticals overvalued?
        According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Terns Pharmaceuticals pay dividends?
          Terns Pharmaceuticals does not currently pay dividends.
          What is Terns Pharmaceuticals’s EPS estimate?
          Terns Pharmaceuticals’s EPS estimate is -$0.31.
            How many shares outstanding does Terns Pharmaceuticals have?
            Terns Pharmaceuticals has 61,794,520 shares outstanding.
              What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
              Terns Pharmaceuticals reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.306. Following the earnings report the stock price went up 5.341%.
                Which hedge fund is a major shareholder of Terns Pharmaceuticals?
                Among the largest hedge funds holding Terns Pharmaceuticals’s share is Fairmount Funds Management Llc. It holds Terns Pharmaceuticals’s shares valued at 10M.

                  Company Description

                  Terns Pharmaceuticals

                  Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

                  Top 5 ETFs holding TERN

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Fidelity MSCI Health Care Index ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold TERN. The ETFs are listed according to market value of TERN within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Corbus Pharmaceuticals
                  Popular Stocks
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis